First Implants of PROPEL® Contour in Patients with Chronic Rhinosinusitis Following Frontal Sinus Surgery in Europe

MENLO PARK, Calif.–(BUSINESS WIRE)–Intersect ENT®, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that Helios Dr. Horst Schmidt Kliniken Wiesbaden in Germany was the first hospital outside the United States to offer the Company’s PROPEL® Contour (mometasone furoate) sinus implant following functional endoscopic sinus surgery (FESS). FESS is used to treat chronic rhinosinusitis, a persistent inflammation of the sinuses that can be debilitating to patients.

Intersect ENT’s PROPEL Contour is a drug-eluting, bioabsorbable sinus implant that is placed in the frontal sinus (between the eyebrows) following sinus surgery. PROPEL Contour incorporates a unique hourglass design that conforms to the sinus openings that delivers an advanced corticosteroid with anti-inflammatory properties and mechanical support to help improve surgical outcomes. PROPEL Contour is clinically proven to reduce the need for additional interventions (surgical treatments and/or oral steroids) after sinus surgery by 65 percent.¹ PROPEL Contour is the third localized drug delivery implant (inclusive of PROPEL and PROPEL Mini), completing the PROPEL family of drug-eluting, bioabsorbable implants now available to ENT specialists in select EU countries.

“After treating my first two patients with PROPEL Contour post-functional endoscopic sinus surgery in August 2021, I was pleased with the design of the PROPEL Contour sinus implant for patients with variable frontal sinus openings that are suffering from chronic rhinosinusitis,” said Prof. Dr. Jan Gosepath, Chairman, Department of Otolaryngology, Head and Neck Surgery, Helios HSK Wiesbaden and Medical Director, Helios Dr. Horst Schmidt Privatklinik Wiesbaden. “With this implant, the surgically enlarged sinus opening can be maintained, and the steroid can be delivered directly to the site where it is needed most to improve postoperative outcomes. At 4-weeks follow-up, both patients showed excellent wound healing, which is what I like to see. Another benefit of the PROPEL Contour implant is that it does not need to be removed and will dissolve after approximately 4-6 weeks.”

About Intersect ENT®

Intersect ENT is a global ear, nose and throat medical technology leader dedicated to transforming patient care. The Company’s steroid releasing implants are designed to provide mechanical spacing and deliver targeted therapy to the site of disease. In addition, Intersect ENT is continuing to expand its portfolio of products based on the Company’s unique localized steroid releasing technology and is committed to broadening patient access to less invasive and more cost-effective care. In October 2020, Intersect ENT acquired Fiagon AG Medical Technologies, a global leader in electromagnetic surgical navigation solutions with an expansive portfolio of ENT product offerings, including the VENSURE sinus dilation balloon, that complement the Company’s PROPEL® family of sinus stents and SINUVA® (mometasone furoate) sinus implants and extend its geographic reach.

For additional information on the Company or the products including risks and benefits, please visit www.IntersectENT.com. For more information about PROPEL® and SINUVA®, please visit www.IntersectENT.de and www.SINUVA.com

Intersect ENT®, PROPEL® and SINUVA® are registered trademarks of Intersect ENT, Inc. VenSure has pending trademark applications.

Important Safety Information for the PROPEL Sinus Implant

The PROPEL Contour sinus implant is intended for use in patients ≥ 18 years of age with chronic rhinosinusitis following sinus surgery to maintain patency of the frontal sinus ostia and to locally deliver mometasone furoate to the sinus mucosa. The PROPEL Contour sinus implant separates/dilates mucosal tissues, prevents obstruction by adhesions/scarring, and reduces edema. The implant reduces the need for post-operative intervention such as surgical adhesion lysis and/or use of oral steroids. For more information on the risks and benefits of PROPEL sinus implants, please visit www.intersectENT.com/products. For use by healthcare professionals only.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Sections 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. We may, in some cases, use terms such as “look forward,” confident,” “promises,” “predicts,” “believe,” “potential,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance or results and may not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. These forward-looking statements are based on Intersect ENT’s current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation those related to the safety, efficacy and patient and physician adoption of the Company’s products and therapies, the ability to obtain and maintain reimbursement codes for its products, the Company’s ability to procure and maintain required regulatory approvals for our products, the Company’s ability to grow and expand its business, as well as other risks detailed from time to time in Intersect ENT’s filings with the Securities and Exchange Commission (SEC), including Intersect ENT’s filings on Form 10-K and Form 10-Q available at the SEC’s Internet site (www.sec.gov). Intersect ENT does not undertake any obligation to update forward-looking statements and expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein.

1. Data on File at Intersect ENT. N=80 in ITT population, with N=61 evaluable patients where both sinuses available for composite endpoint. Results judged by independent reviewer.

Contacts

IR:

Randy Meier, 650-641-2105

Executive Vice-President & CFO

ir@intersectENT.com

Media:

Erich Sandoval, 917-497-2867

Finn Partners for Intersect ENT

IntersectENT@finnpartners.com